Condition
Relapsed or Refractory Plasma Cell Neoplasms
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Early P 1 (3)
Trial Status
Not Yet Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT07519187Early Phase 1Not Yet RecruitingPrimary
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
NCT06986434Early Phase 1Not Yet RecruitingPrimary
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
NCT07077330Early Phase 1Not Yet RecruitingPrimary
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms
Showing all 3 trials